Pro-Dex (NASDAQ:PDEX - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 13th. Analysts expect Pro-Dex to post earnings of $0.38 per share and revenue of $13.80 million for the quarter.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Pro-Dex Stock Down 2.2 %
Shares of PDEX stock traded down $0.75 during mid-day trading on Friday, hitting $33.59. 23,009 shares of the stock traded hands, compared to its average volume of 30,680. Pro-Dex has a 52-week low of $16.18 and a 52-week high of $59.60. The stock has a market cap of $109.50 million, a P/E ratio of 16.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock's fifty day moving average is $45.78 and its two-hundred day moving average is $35.15.
Insiders Place Their Bets
In related news, Director Raymond E. Cabillot sold 1,200 shares of Pro-Dex stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $47.76, for a total value of $57,312.00. Following the sale, the director now directly owns 359,646 shares in the company, valued at approximately $17,176,692.96. The trade was a 0.33 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 27,770 shares of company stock worth $1,239,312. 47.50% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
PDEX has been the topic of a number of research analyst reports. StockNews.com lowered shares of Pro-Dex from a "strong-buy" rating to a "buy" rating in a report on Monday, February 3rd. Ascendiant Capital Markets increased their price objective on Pro-Dex from $30.00 to $52.00 and gave the company a "buy" rating in a report on Monday, November 11th.
Check Out Our Latest Stock Analysis on Pro-Dex
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Further Reading
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
